Adjuvant Chemotherapy for High Malignant Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2031

Conditions
Prostate CancerRadiation TherapyChemotherapyGleason Score
Interventions
DRUG

Docetaxel

Chemotherapy will start 4-8 weeks after the completion of radiotherapy. The chemotherapy regimen will consist of docetaxel 75 mg/m² administered intravenously on Day 1, repeated every 21 days for a total of 4-6 cycles. In cases of significant neuroendocrine differentiation and if well-tolerated, a combination of docetaxel and carboplatin (docetaxel 75 mg/m² and carboplatin AUC 4-6) will be used. Pre-treatment with dexamethasone will be administered to reduce potential side effects.

Trial Locations (2)

100034

RECRUITING

Peking University First Hospital, Beijing

Unknown

RECRUITING

Peking University Shenzhen Hospital, Shenzhen

All Listed Sponsors
collaborator

Peking University Shenzhen Hospital

OTHER

lead

Peking University First Hospital

OTHER

NCT06864533 - Adjuvant Chemotherapy for High Malignant Prostate Cancer | Biotech Hunter | Biotech Hunter